Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study.

J Immunother Cancer · 2025 · PMC11804207 · PMID 39915262

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

did not reach statistical significancep=0.10so close (0.05 < p ≤ 0.1)

Of the patients treated in the NKI, hybrid dosed patients had a non-inferior OS (HR 0.74, p<0.0001, figure 5A ), but for patients treated at the LUMC, this did not reach statistical significance (HR 0.43, p=0.10, figure 5B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.